Cargando…
Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia
Acute lymphoblastic leukemia (ALL) has been generally considered a genetic disease (disorder) with an aggressive tumor entity of highly proliferative malignant lymphoid cells. However, in recent years, significant advances have been made in the elucidation of the ALL-associated processes. Thus, we u...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634719/ https://www.ncbi.nlm.nih.gov/pubmed/26543507 http://dx.doi.org/10.1186/s13148-015-0151-8 |
_version_ | 1782399404420890624 |
---|---|
author | Zhang, Cheng Zhong, Jiang F. Stucky, Andres Chen, Xue-Lian Press, Michael F. Zhang, Xi |
author_facet | Zhang, Cheng Zhong, Jiang F. Stucky, Andres Chen, Xue-Lian Press, Michael F. Zhang, Xi |
author_sort | Zhang, Cheng |
collection | PubMed |
description | Acute lymphoblastic leukemia (ALL) has been generally considered a genetic disease (disorder) with an aggressive tumor entity of highly proliferative malignant lymphoid cells. However, in recent years, significant advances have been made in the elucidation of the ALL-associated processes. Thus, we understand that histone acetylation is involved in the permanent changes of gene expression controlling ALL developmental outcomes. In this article, we will focus on histone acetylation associated with ALL, their implications as biomarkers for prognostic, and their preclinical and clinical applications. |
format | Online Article Text |
id | pubmed-4634719 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46347192015-11-06 Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia Zhang, Cheng Zhong, Jiang F. Stucky, Andres Chen, Xue-Lian Press, Michael F. Zhang, Xi Clin Epigenetics Review Acute lymphoblastic leukemia (ALL) has been generally considered a genetic disease (disorder) with an aggressive tumor entity of highly proliferative malignant lymphoid cells. However, in recent years, significant advances have been made in the elucidation of the ALL-associated processes. Thus, we understand that histone acetylation is involved in the permanent changes of gene expression controlling ALL developmental outcomes. In this article, we will focus on histone acetylation associated with ALL, their implications as biomarkers for prognostic, and their preclinical and clinical applications. BioMed Central 2015-11-04 /pmc/articles/PMC4634719/ /pubmed/26543507 http://dx.doi.org/10.1186/s13148-015-0151-8 Text en © Zhang et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Zhang, Cheng Zhong, Jiang F. Stucky, Andres Chen, Xue-Lian Press, Michael F. Zhang, Xi Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia |
title | Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia |
title_full | Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia |
title_fullStr | Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia |
title_full_unstemmed | Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia |
title_short | Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia |
title_sort | histone acetylation: novel target for the treatment of acute lymphoblastic leukemia |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634719/ https://www.ncbi.nlm.nih.gov/pubmed/26543507 http://dx.doi.org/10.1186/s13148-015-0151-8 |
work_keys_str_mv | AT zhangcheng histoneacetylationnoveltargetforthetreatmentofacutelymphoblasticleukemia AT zhongjiangf histoneacetylationnoveltargetforthetreatmentofacutelymphoblasticleukemia AT stuckyandres histoneacetylationnoveltargetforthetreatmentofacutelymphoblasticleukemia AT chenxuelian histoneacetylationnoveltargetforthetreatmentofacutelymphoblasticleukemia AT pressmichaelf histoneacetylationnoveltargetforthetreatmentofacutelymphoblasticleukemia AT zhangxi histoneacetylationnoveltargetforthetreatmentofacutelymphoblasticleukemia |